These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 22201947

  • 1. FVIIa as therapeutic agent in hemophilia and beyond.
    Hedner U.
    Front Biosci (Elite Ed); 2012 Jan 01; 4(4):1210-23. PubMed ID: 22201947
    [Abstract] [Full Text] [Related]

  • 2. General haemostatic agents--fact or fiction?
    Hedner U.
    Pathophysiol Haemost Thromb; 2002 Jan 01; 32 Suppl 1():33-6. PubMed ID: 12214145
    [Abstract] [Full Text] [Related]

  • 3. New insights into the coagulation system and implications for new therapeutic options with recombinant factor VIIa.
    Veldman A, Hoffman M, Ehrenforth S.
    Curr Med Chem; 2003 May 01; 10(10):797-811. PubMed ID: 12678684
    [Abstract] [Full Text] [Related]

  • 4. Mechanism of action, development and clinical experience of recombinant FVIIa.
    Hedner U.
    J Biotechnol; 2006 Aug 05; 124(4):747-57. PubMed ID: 16697480
    [Abstract] [Full Text] [Related]

  • 5. History of rFVIIa therapy.
    Hedner U.
    Thromb Res; 2010 Apr 05; 125 Suppl 1():S4-6. PubMed ID: 20188400
    [Abstract] [Full Text] [Related]

  • 6. Potential role of recombinant factor VIIa as a hemostatic agent.
    Hedner U, Erhardtsen E.
    Clin Adv Hematol Oncol; 2003 Feb 05; 1(2):112-9. PubMed ID: 16224390
    [Abstract] [Full Text] [Related]

  • 7. The role of recombinant factor VIIa (FVIIa) in fibrin structure in the absence of FVIII/FIX.
    He S, Blombäck M, Jacobsson Ekman G, Hedner U.
    J Thromb Haemost; 2003 Jun 05; 1(6):1215-9. PubMed ID: 12871322
    [Abstract] [Full Text] [Related]

  • 8. First 20 years with recombinant FVIIa (NovoSeven).
    Hedner U, Lee CA.
    Haemophilia; 2011 Jan 05; 17(1):e172-82. PubMed ID: 20609014
    [Abstract] [Full Text] [Related]

  • 9. Recombinant factor VIIa: its background, development and clinical use.
    Hedner U.
    Curr Opin Hematol; 2007 May 05; 14(3):225-9. PubMed ID: 17414211
    [Abstract] [Full Text] [Related]

  • 10. The effect of platelets on fibrin gel structure formed in the presence of recombinant factor VIIa in hemophilia plasma and in plasma from a patient with Glanzmann thrombasthenia.
    He S, Ekman GJ, Hedner U.
    J Thromb Haemost; 2005 Feb 05; 3(2):272-9. PubMed ID: 15670032
    [Abstract] [Full Text] [Related]

  • 11. Mechanism of action of factor VIIa in the treatment of coagulopathies.
    Hedner U.
    Semin Thromb Hemost; 2006 Apr 05; 32 Suppl 1():77-85. PubMed ID: 16673269
    [Abstract] [Full Text] [Related]

  • 12. Tissue factor and factor VIIa as therapeutic targets in disorders of hemostasis.
    Hedner U, Ezban M.
    Annu Rev Med; 2008 Apr 05; 59():29-41. PubMed ID: 17845136
    [Abstract] [Full Text] [Related]

  • 13. The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis.
    Hoffman M, Monroe DM.
    Dis Mon; 2003 Jan 05; 49(1):14-21. PubMed ID: 12525825
    [Abstract] [Full Text] [Related]

  • 14. Factor VIIa and its potential therapeutic use in bleeding-associated pathologies.
    Hedner U.
    Thromb Haemost; 2008 Oct 05; 100(4):557-62. PubMed ID: 18841276
    [Abstract] [Full Text] [Related]

  • 15. In vitro evidence of a tissue factor-independent mode of action of recombinant factor VIIa in hemophilia.
    Augustsson C, Persson E.
    Blood; 2014 Nov 13; 124(20):3172-4. PubMed ID: 25232061
    [Abstract] [Full Text] [Related]

  • 16. Administration of recombinant FVIIa (rFVIIa) to concizumab-dosed monkeys is safe, and concizumab does not affect the potency of rFVIIa in hemophilic rabbits.
    Lauritzen B, Olling J, Abel KL, Augustsson C, Balling K, Bjelke M, Hegelund AC, Hilden I.
    J Thromb Haemost; 2019 Mar 13; 17(3):460-469. PubMed ID: 30614620
    [Abstract] [Full Text] [Related]

  • 17. NovoSeven as a universal haemostatic agent.
    Hedner U.
    Blood Coagul Fibrinolysis; 2000 Apr 13; 11 Suppl 1():S107-11. PubMed ID: 10850574
    [Abstract] [Full Text] [Related]

  • 18. A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone.
    Tomokiyo K, Nakatomi Y, Araki T, Teshima K, Nakano H, Nakagaki T, Miyamoto S, Funatsu A, Iwanaga S.
    Vox Sang; 2003 Nov 13; 85(4):290-9. PubMed ID: 14633255
    [Abstract] [Full Text] [Related]

  • 19. Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII.
    Hoffman M, Monroe DM, Roberts HR.
    Blood Coagul Fibrinolysis; 1998 Mar 13; 9 Suppl 1():S61-5. PubMed ID: 9819030
    [Abstract] [Full Text] [Related]

  • 20. The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis.
    Hoffman M, Monroe DM.
    Semin Hematol; 2001 Oct 13; 38(4 Suppl 12):6-9. PubMed ID: 11735103
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.